DK3326611T3 - Formulering af doxylamin og pyridoxin og / eller metaboliter eller salt deraf - Google Patents

Formulering af doxylamin og pyridoxin og / eller metaboliter eller salt deraf Download PDF

Info

Publication number
DK3326611T3
DK3326611T3 DK17195445.6T DK17195445T DK3326611T3 DK 3326611 T3 DK3326611 T3 DK 3326611T3 DK 17195445 T DK17195445 T DK 17195445T DK 3326611 T3 DK3326611 T3 DK 3326611T3
Authority
DK
Denmark
Prior art keywords
pyridoxin
doxylamine
metabolites
formulation
salts
Prior art date
Application number
DK17195445.6T
Other languages
English (en)
Inventor
Manon Vranderick
Jean-Luc St-Onge
Christelle Gedeon
Michele Gallo
Éric Gervais
Original Assignee
Duchesnay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49004884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3326611(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duchesnay Inc filed Critical Duchesnay Inc
Application granted granted Critical
Publication of DK3326611T3 publication Critical patent/DK3326611T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK17195445.6T 2012-02-22 2013-02-18 Formulering af doxylamin og pyridoxin og / eller metaboliter eller salt deraf DK3326611T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261601754P 2012-02-22 2012-02-22
EP13751706.6A EP2787971A4 (en) 2012-02-22 2013-02-18 FORMULATION OF DOXYLAMINE AND PYRIDOXINE AND / OR THEIR METABOLITES OR SALTS

Publications (1)

Publication Number Publication Date
DK3326611T3 true DK3326611T3 (da) 2020-08-17

Family

ID=49004884

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17195445.6T DK3326611T3 (da) 2012-02-22 2013-02-18 Formulering af doxylamin og pyridoxin og / eller metaboliter eller salt deraf

Country Status (25)

Country Link
US (3) US9089489B2 (da)
EP (2) EP2787971A4 (da)
JP (2) JP5914701B2 (da)
KR (1) KR101588259B1 (da)
CN (1) CN104136004B (da)
AR (2) AR090126A1 (da)
AU (1) AU2013224598B2 (da)
BR (1) BR112014020186A8 (da)
CA (1) CA2848798C (da)
CL (1) CL2014001828A1 (da)
CY (1) CY1123122T1 (da)
DK (1) DK3326611T3 (da)
ES (1) ES2809713T3 (da)
HK (1) HK1197035A1 (da)
HU (1) HUE052301T2 (da)
IL (1) IL233644A (da)
LT (1) LT3326611T (da)
MX (1) MX355912B (da)
NZ (1) NZ627593A (da)
PL (1) PL3326611T3 (da)
PT (1) PT3326611T (da)
SG (1) SG11201403931YA (da)
TW (1) TWI638657B (da)
UY (1) UY34631A (da)
WO (1) WO2013123595A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2787971A4 (en) 2012-02-22 2015-04-29 Duchesnay Inc FORMULATION OF DOXYLAMINE AND PYRIDOXINE AND / OR THEIR METABOLITES OR SALTS
JP6379194B2 (ja) 2013-07-22 2018-08-22 デュシネイ・インコーポレイテッド 悪心及び嘔吐の管理のための組成物
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting
CN103432126A (zh) * 2013-08-05 2013-12-11 北京阜康仁生物制药科技有限公司 一种治疗孕吐的药物组合物
MX360662B (es) * 2014-08-29 2018-11-13 Duchesnay Inc Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas.
EP3337480A4 (en) 2015-08-17 2019-05-08 Aequus Pharmaceuticals Inc. TRANSDERMAL DELIVERY OF DOXYLAMINE SUCCINATE AND PIRIDOXINE HYDROCHLORIDE
EP3697392B1 (en) 2017-10-17 2023-11-15 Synthon B.V. Tablets comprising tamsulosin and solifenacin
HUE053082T2 (hu) * 2018-09-27 2021-06-28 Inibsa Ginecologia S A Eljárás doxilamin-szukcinát- és piridoxin-hidroklorid-tartalmú, módosított hatóanyag-leadású, több kis egységet tartalmazó, orális adagolási forma elõállítására
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación
WO2022254277A1 (en) * 2021-05-31 2022-12-08 Maneesh Pharmaceuticals Ltd Extended release composition and its process for the preparation
AU2021225255B1 (en) * 2021-09-03 2022-06-16 Patel, Mihir MR Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting.

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US4842867A (en) 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US5110597A (en) 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
NZ286242A (en) 1991-03-26 1997-11-24 Csl Ltd Use of veterinary implant as a single dose vaccination system: rupturable polymer film coating around core of active agent and water soluble excipient
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US7744916B2 (en) 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
JP2002541092A (ja) 1999-04-06 2002-12-03 ファーマクエスト・リミテッド メチルフェニデートのパルス性送達のための薬学的投薬形態
US6197329B1 (en) * 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
WO2001037721A2 (en) 1999-11-22 2001-05-31 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
CA2350195C (en) 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
EP1372602B1 (en) 2001-01-09 2007-04-18 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7704542B2 (en) 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
CA2495327C (en) 2002-08-16 2008-10-21 Microchips, Inc. Controlled release device and method using electrothermal ablation
GB0229725D0 (en) 2002-12-19 2003-01-29 Univ Wales Medicine Haplotype partitioning and growth hormone SNPs
EP1791643B1 (en) 2004-09-01 2009-03-11 Microchips, Inc. Multi-cap reservoir devices for controlled release or exposure of reservoir contents
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
WO2009035033A1 (ja) 2007-09-14 2009-03-19 Rohto Pharmaceutical Co., Ltd. 眼科用組成物
KR101190708B1 (ko) * 2010-03-12 2012-10-12 주식회사 대웅제약 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
EP2555756B1 (en) * 2010-04-07 2018-08-22 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
AU2011271124A1 (en) * 2010-06-22 2013-01-10 Twi Pharmaceuticals, Inc. Controlled release compositions with reduced food effect
WO2013123569A1 (en) 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
EP2787971A4 (en) 2012-02-22 2015-04-29 Duchesnay Inc FORMULATION OF DOXYLAMINE AND PYRIDOXINE AND / OR THEIR METABOLITES OR SALTS
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting

Also Published As

Publication number Publication date
CL2014001828A1 (es) 2014-11-14
NZ627593A (en) 2015-12-24
MX355912B (es) 2018-05-04
AR090126A1 (es) 2014-10-22
UY34631A (es) 2013-09-30
WO2013123595A1 (en) 2013-08-29
CY1123122T1 (el) 2021-10-29
JP2016053092A (ja) 2016-04-14
KR101588259B1 (ko) 2016-01-25
SG11201403931YA (en) 2014-08-28
PL3326611T3 (pl) 2020-11-02
EP3326611A1 (en) 2018-05-30
US20150366808A1 (en) 2015-12-24
BR112014020186A2 (da) 2017-06-20
AU2013224598A1 (en) 2014-07-31
EP2787971A1 (en) 2014-10-15
TWI638657B (zh) 2018-10-21
PT3326611T (pt) 2020-08-20
AU2013224598B2 (en) 2015-09-17
JP5914701B2 (ja) 2016-05-11
ES2809713T3 (es) 2021-03-05
EP3326611B1 (en) 2020-05-06
IL233644A (en) 2016-05-31
JP2015508082A (ja) 2015-03-16
CA2848798C (en) 2014-12-23
AR122580A2 (es) 2022-09-21
IL233644A0 (en) 2014-08-31
US9089489B2 (en) 2015-07-28
US9937132B2 (en) 2018-04-10
BR112014020186A8 (pt) 2017-07-11
US9375404B2 (en) 2016-06-28
CA2848798A1 (en) 2013-08-29
CN104136004B (zh) 2018-03-06
US20140314680A1 (en) 2014-10-23
TW201334780A (zh) 2013-09-01
HUE052301T2 (hu) 2021-04-28
MX2014008594A (es) 2015-03-03
US20160374946A1 (en) 2016-12-29
EP2787971A4 (en) 2015-04-29
HK1197035A1 (en) 2015-01-02
KR20140139496A (ko) 2014-12-05
LT3326611T (lt) 2020-08-25
CN104136004A (zh) 2014-11-05

Similar Documents

Publication Publication Date Title
DK3326611T3 (da) Formulering af doxylamin og pyridoxin og / eller metaboliter eller salt deraf
DK3043785T3 (da) Anvendelse af r-ketamin og salt deraf som lægemidler
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3184519T3 (da) Syreadditionssalt af trk-hæmmende forbindelse
DK3027618T3 (da) Polymorf af syk-hæmmere
DK2958588T3 (da) Kombination af vaccination og hæmning af PD-1-reaktionsvejen
DK2845905T3 (da) Fremstilling af oligosaccharider
DK2892550T3 (da) Stabile vandige formuleringer af adalimumab
DK3608325T3 (da) Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
DK2906696T4 (da) Fremgangsmåder til modulering af c9orf72-ekspression
DK3235824T3 (da) Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat
DK3363901T3 (da) Sammensætninger og fremgangsmåder til præcis identificering af mutationer
DK2724135T3 (da) Dynamisk tredimensional billeddannelse af øregange
DK2892912T3 (da) C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
DK2968221T3 (da) Farmaceutisk sammensætning af s-ketaminhydrochlorid
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK2846809T3 (da) Behandling af myelosuppression
DK3450434T3 (da) Deutererede derivater af ruxolitinib
DK3461895T3 (da) Modulation af ube3a-ats-ekspression
DK2917358T3 (da) Sammensætninger og fremgangsmåder til biologisk fremstilling af fedtsyrederivater
DK2909182T3 (da) Fremstilling af og formulering omfattende en mek-inhibitor
DK2832740T3 (da) SALT AF 1-(2-DEOXY-2-FLUOR-4-THIO-beta-D-ARABINOFURANOSYL)CYTOSIN
DK2782565T3 (da) Anvendelse af aryl- og hetarylcarboxamider som endoparasiticider
DK2822568T3 (da) Anvendelser af caseinsammensætninger
DK2919777T3 (da) Transmukosal afgivelse af tocotrienol